Table 4.

Odds ratios (OR) and 95% confidence intervals for the predictive factors at inclusion on controlled and uncontrolled asthma at 3 months.

Parameters		Well controlled asthma
		Defined by GINA			Defined by ACT scores ≥ 20
		OR (min/max)	CI 95%	P	OR	CI 95%	P
Clinical characteristics*
Asthma onset >5 years (+)		1.3	0.5 / 1.8	NS	1.5	0.8 / 1.9	NS
Passive smoker (-)		1.4	0.7 / 2.1	NS	1.3	0.7 / 1.8	NS
Asthma severity	Moderate (+)	3.1	1.8 / 5.3	<0.01	2.3	1.6 / 4.1	<0.05
	Severe (-)	3.3	1.7 / 5.9	<0.01	2.9	1.4 / 4.8	<0.05
AAE hospitalized in previous year ≥2 times (-)		1.9	0.9 / 2.9	<0.05	1.7	0.6 / 3.1	NS
Daily used SABA ≥2 buffs§ (-)		1.8	0.8 / 2.7	<0.05	1.5	0.7 / 2.7	NS
Allergic rhinitis (-)		1.5	0.7 / 2.9	NS	1.4	0.7 / 2.4	<0.05
Functional characteristics*
FEV1, %	<60 (-)	1.8	0.1 / 4.1	<0.05	1.4	0.9 / 3.9	NS
	60 – 80 (+)	0.9	0.5 / 2.1	NS	0.7	0.2 / 1.9	NS
	≥ 80 (+)	1.6	0.9 / 3.2	<0.05	1.5	0.7 / 3.8	<0.05
nNO, ppb	>500 (-)	1.4	0.7 / 3.5	NS	1.3	0.6 / 3.1	NS
	500-1000 (-)	1.5	0.5 / 3.1	NS	1.4	0.8 / 2.4	NS
	>1000 (-)	1.3	0.7 / 3.1	NS	0.9	0.4 / 2.7	NS
FENO, ppb	<20 (-)	1.7	0.8 / 3.3	<0.05	1.5	0.9 / 3.1	<0.05
	20 – 35 (+)	1.3	0.3 / 3.4	NS	0.9	0.4 / 2.9	NS
	>35 (+)	3.5	2.2 / 5.9	<0.01	2.9	1.4 / 4.9	NS
CANO, ppb	>5 (-)	1.9	0.9 / 2.7	<0.05	1.5	0.8 / 2.6	<0.05
	≤5 (+)	0.8	0.2 / 1.7	NS	0.7	0.3 / 1.9	NS
	<300 (+)	0.9	0.3 / 2.1	<0.05	0.7	0.2 / 1.8	NS
BEC, cells/μL	300-600 (+)	1.6	0.8 / 3.5	NS	1.4	0.7 / 2.9	NS
	≥600 (-)	1.3	0.6 / 2.3	NS	1.2	0.5 / 2.1	NS

AAE, acute asthma exacerbation; SABA, short acting beta 2 agonist; FEV₁, forced expiratory volume in 1 s; FE_NO, fractional exhaled nitric oxide; CA_NO, concentration of nitric oxide in the gas phase of the alveolar; Fn_NO, fractional concentration of nasally aspirated nitric oxide; ppb, part per billion; BEC, blood eosinophil count; NS, not significant difference

^*measured at inclusion

^§measured at 1 month; (-), risk of uncontrolled asthma; (+), positive agreement of controlled asthma.